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INTRODUCTION
Lung cancer continues to be the major cancer killer in 
both sexes world-wide (1). Approximately 1.6 million new 
cases of lung cancer are diagnosed each year (2). While 
the number of cases continues to increase in many places 
around the world, the overall cure rate from lung cancer 
is modest (approximately 17%) because the majority of 
patients present with advanced stage at diagnosis. This is 
irrespective of refinements in histological aspects, better 
diagnostic and staging tools – including massive influence 
of positron emission tomography (PET) scanning – and 
a sharp shift towards molecular oncology already finding 
its way to clinics. The most recent update of staging 
by the International Association for the Study of Lung 
Cancer (IASLC) provided an important addition to the 
issue (3). Therefore treatment paradigm may be seen 
as even more important nowadays, since it ultimately 
should match pre-treatment advances. Although many 
treatment modalities are employed in lung cancer, each 
of which continues to develop, we will concentrate on 
the non-surgical ones, namely radiation therapy (RT) 
and drug therapy, which includes both chemotherapy 
(CHT) and targeted therapy used in both non-small-cell 
lung cancer (NSCLC) and small-cell lung cancer (SCLC). 
This article focuses on current aspects of non-surgical 
treatments in lung cancer since they are the domain of 
expertise of oncologists at the Division of Radiation and 
Clinical Oncology of the Stellenbosch University and its 
affiliated Tygerberg Hospital which is housed in a facility 
known as “Building X”. Ultimately, the goal is to confront 
worldwide state-of-the-art treatment in this disease with 
local/national realities, identifying both obstacles and 
opportunities in this setting.
TECHNOLOGY
 In recent decades computerised techniques and 
software had a significant impact on radiation oncology. 
With the advent of computed tomography (CT) and 
magnetic resonance imaging (MRI) radiation oncologists 
were able to move away from “classic” two-dimensional 
(2D) to three-dimensional (3D) planning. Increasing 
software capabilities enabled more focused irradiation 
of tumours and less irradiation to surrounding normal 
tissues. This also meant that with better RT field shaping, 
an increase in the RT dose delivered to tumours became 
possible. In lung cancer, numerous such studies in 3D RT 
showed promise (4, 5) which led to better local control 
and overall survival.
Translating existing knowledge and techniques into 
routine clinical use can present significant challenges, but 
is essential for improving the effectiveness of RT and 
improving local control and survival (6). Over the last 
two decades a convergence of technologies has helped 
to shape modern day RT, including four-dimensional 
RT (4DRT) for lung cancer and the use of PET-CT in 
treatment planning of irradiation of lung cancer. Four-
dimensional lung RT makes it possible to identify and 
account for breathing related tumour and organ at risk 
(OAR) motion during RT planning and delivery. This 
concept is not new as the movement of lung tumours 
and surrounding structures was also appreciated during 
treatment simulation in the 2DRT era. However, at a 
time when the prognosis for many patients with lung 
cancer remains poor, many technical advances have failed 
to enter routine clinical use, even once the available 
technology has been acquired (7, 8). Although the 
explanations for this will likely vary between healthcare 
systems, one probable reason is that useful developments 
in RT are sometimes seen as difficult to implement, or 
perceived as too complex or time consuming for day 
to day use. Frequently, a lack of resources is implicated 
(7); however, all too often a systematic and focused 
approach to change and implementation may be 
lacking (9). Under such conditions the risk is high that 
technology implementation projects will fail, deliver 
below expectation or take a very long time to complete, 
adversely affecting their ability to impact positively on 
patient outcomes.
Another aspect of treatment planning in lung cancer, 
widely accepted as “new standard” in well-chosen 
cases, includes PET-CT-based treatment planning. The 
burgeoning PET and PET-CT literature clearly shows 
4that an estimate of disease extent based on PET is very 
frequently different from and is usually more accurate 
than an estimate made using CT alone. In a growing 
number of studies in the literature, PET- or PET-CT-
based RT planning has been compared with planning 
using CT alone, using each patient as their own control. 
Comparisons between RT treatment plans or tumour 
volumes made with and without the assistance of PET 
have been made. PET-based RT planning has been 
shown to have an especially high impact on patients 
with atelectasis. On CT scans, atelectatic lung and 
tumour tissues typically have similar densities. The lack of 
contrast makes it impossible for the radiation oncologist 
to do anything other than guess where the boundary 
between tumour and lung lies. However, when CT 
information is supplemented by FDG-PET information, 
especially in the form of a fused PET-CT image, it is often 
very easy to determine the boundary between normal 
tissue and tumour, thereby attaining tumour coverage 
with the least exposure of uninvolved lung. Prospective 
and retrospective trials in which PET and PET/CT have 
been used for RT planning in lung cancer have shown 
a clinically significant impact of PET, although most 
studies were small. It is currently impossible to quantify 
the benefit of PET-based planning, but it is reasonable 
to assume that a treatment plan made using a more 
accurate estimate of tumour extent is going to be a 
better one.
So, where does this leave things? Our own department, 
which operates within the serious constraints of a public 
healthcare system, aims to create an environment 
that is receptive to the rapid adoption of new 
technologies and techniques that can make a specific 
treatment possible, permit the delivery of potentially 
toxic treatment with a lower predicted risk or enable 
greater efficiency. Technology is an enabler but the most 
important component of the treatment chain remains 
the radiation and how, when and where it is used. These 
aspects are taken into account by practicing principles of 
evidence-based oncology (EBO) with clearly delineated 
institutional diagnostic and treatment protocols. 
While taking into account worldwide achievements, 
accumulated evidence after investigating patterns of 
practice in this setting was considered an important 
additive to the decision-making process (10). It enabled 
identification of professional, scientific but also non-
medical reasons that needed to be taken into account. 
As a result, adaptation to the limited resource setting 
of developing countries was considered as an absolute 
prerequisite for meaningful implementation of the RT 
approach in circumstances where access to RT seemed 
to be of paramount importance (11). After purchasing 
a Big Bore CT scanner (Philips, The Netherlands) we 
became capable of using information gathered during the 
scanning process (including synchronisation of breathing 
cycles with tumour movements in 3D fashion) to create 
target volumes (that include such movements) being 
now more closely shaped than without it. This should 
result in better target coverage and less normal tissue 
being exposed to irradiation, hence better therapeutic 
ratio. This became standard procedure for all patients 
treated with curative intent, similar to the experiences 
worldwide the past decade. The next step would include 
4D treatment delivery, once novel linear accelerators 
become available coupled with 4D irradiation, which 
currently available linear accelerators in Building X do 
not have. In addition, the sophisticated new Big Bore CT 
scanning process enables implementation of another 
important RT technique, known as intensity modulated 
radiation therapy (IMRT).
BIOLOGY
Lung carcinoma is a disease which is characterised 
by several genetic and molecular biological changes 
which contribute to carcinogenesis by the activation of 
oncogenes or inactivation of tumour suppressor genes. 
In the past 20 years we have substantially increased our 
knowledge in this field as well as enhanced our skills 
in detecting these changes. Various groups of factors, 
proteins, genes and proto-oncogenes as well as small 
molecules have been identified and related to different 
processes. This has largely helped more sophisticated 
histological refinements, ultimately leading to recent 
histological classifications. Knowledge gathered eventually 
also lead to the engineering of specific drugs to be used 
in clinics. Due to their “targeted” nature, they have all 
been frequently grouped among “targeted agents” to 
differentiate them from more classically used, systemic 
drug therapy (also known as chemotherapy). It was 
assumed that this “targeted” nature would allow for more 
specific (hence, better) effectiveness and, consequently, 
less toxicity. Some of the most investigated molecular 
abnormalities are listed in Table 1. 
MOLECULAR ABNORMALITIES IN LUNG CANCER CELLS
5In spite of booming clinical research in this field and 
approval by the FDA in the USA for several classes of 
targeted agents, molecular events on cellular level are still 
not completely demystified (see Figure 1). This represents 
a serious call for more preclinical research in lung cancer, 
largely considered vitally dependent on incorporation of 
novel biological aspects in existing treatment paradigms. 
CLINICAL SCIENCE
Lung cancer has been and still is one of the major 
battlegrounds in clinical oncology. The highest level of 
EBO, i.e. prospective randomised clinical trials and meta-
analyses, is continuously shaping the existing knowledge 
and influencing the decision-making process. As such, 
they exist in all lung cancer stages and both histological 
forms investigated. 
In early stage (I–II) NSCLC, RT has traditionally been used 
in patients technically operable, but deemed medically 
inoperable due to existing comorbidities, producing 
Growth Signals NSCLC SCLC 
Ras 25 <1 
Akt 70-90 65 
Myc 20- 60 20-30 
EGFR 50 0-50 
HER2/neu 30 30 
c-Kit 30- -40 50 
Neuropeptides ~50 ~50 
IGF ~90 ~90 
Tumor Suppressor Genes   
RB 15- -30 >90 
p16(INK4A) inactivation 50-70 0-20 
3p deletions 70 90 
FHIT inactivation 40-70 70 
RASSFIA silencing 50 90 
Apoptosis   
p53 40-50 60-75 
Bcl-2 20-35 71 
Replicative Potential   
Telomerase 80-100 80-100 
Angiogenesis   
VEGF 75 75 
COX-2 >70 Not reported 
Metastasis   
N-CAML, non-adhesive Not reported 90 
Laminin-5 inactivation 20-60 68-85 
 
Table 1 Frequency of molecular abnormalities in lung cancer 
median survival times (MSTs) of 24 to 36 months 
and five-year survivals of 25–35% (12–17), though still 
significantly inferior to surgical reports. However, patients 
treated with RT alone are deemed as “very unfavourable” 
(comorbidities, understaging, clinical staging) and hence, 
not directly comparable to their surgical counterparts. 
Finally, when one takes into account cancer-unrelated 
deaths and correct the outcomes by using cancer-specific 
or cause-specific survival as an endpoint, RT results 
become much better (18). Recent decades also brought 
novel RT technologies into this setting. First 3DRT (4, 
5) and then stereotactic body radiation therapy (SBRT) 
have been used with increasing frequency in medically 
inoperable patients with stage I–II NSCLC. Initial single-
institutional reports on SBRT were followed by a number 
of prospective phase II studies around the globe which all 
showed excellent results (local control, 80–95%; three-
year survival, 60–70%) irrespective of the technique 
and dose-fractionation parameters used (19–22). These 
encouraging results were coupled with retrospective 
reports from various institutions directly comparing 
surgical to RT cohorts of patients. These reports (23, 24) 
showed similarity in overall results (local control, overall 
survival, toxicity) and called for more formal comparison, 
using prospective randomised trial settings. Two on-going 
studies in the USA comparing surgery to RT should 
shed more light on the problem of preferred treatment 
option in patients with stage I–II NSCLC. 
In locally advanced (stage III) NSCLC, three recent meta-
analyses (25–27) reconfirmed findings of previous clinical 
trials that concurrent RT-CHT is superior to RT alone 
(28, 29) and sequential RT-CHT (30, 31), establishing 
it as the standard treatment in the last decade. While 
some studies indicated that concurrent RT-CHT can 
have more side-effects (32, 34), those studies used high-
dose RT and concurrently given high-dose CHT. When, 
on the other side, high-dose RT was combined with 
low-dose (mostly given daily) CHT, side-effects became 
much less frequent (28, 29). Importantly, this particular 
approach (concurrent RT and low-dose CHT) achieved 
the best overall results with MSTs of more than 20 
months and an overall five-year survival rate of more 
than 20%. Furthermore, concurrent RT-CHT proved 
to be an effective and low-toxic approach in the most 
“favourable” subgroup of patients with stage IIIA NSCLC 
in which several attempts to optimise outcome failed 
when surgery was included. Data from prospective 
randomised trials showed that concurrent RT-CHT was 
not inferior to neoadjuvant RT-CHT followed by surgery 
(35, 35) and, as recently shown (37, 38), exclusive and 
concurrent RT-CHT can produce results (MST, 38 
months; five-year survival, 41%) which seem better than 
those produced in any of the surgical studies done so far. 
6In spite of being staged as locally advanced (non-
metastatic) NSCLC, some patients are deemed 
incurable from the outset, mostly those with bulky 
tumours and unfavourable clinical characteristics (e.g. 
poor performance status, pronounced weight loss). In 
this patient population, RT has been frequently used 
to palliate existing symptoms and, if possible, prolong 
life. Until the first study from the UK Medical Research 
Council (MRC) was published in 1991 (39), a typical 
course was 30 Gy in 10 fractions (fx). Since then, several 
randomised phase III trials (40–47) compared a short-
course RT (8 or 10 Gy/1fx or 17 Gy/2fx or 16 Gy/2fx) 
to a normo-fractionated RT ranging 20–50 Gy. In two 
trials (45, 46) the effect on symptoms was in favour of 
the higher dose; otherwise the effect on disease-related 
symptoms were equal. In three trials (41, 43, 46) the 
survival was in favour of the high-dose arm; 39 Gy/13fx, 
30 Gy/10fx and 30 Gy/10fx, respectively. One trial (47) 
reported a survival benefit for 16 Gy/2fx versus 20 
Gy/5fx. In another trial (44), 17 Gy/2fx was compared 
with two high-dose arms; 42 Gy/15fx and 50 Gy/25fx, 
with no difference in MST found. Five randomised phase 
III studies (48–52) have compared different normo- to 
high-dose regimens. Nearly all had stage III localised 
disease with WHO performance status (PS) 0–2. One 
study reported better palliation in the high-dose arm 
(66). Four studies provided data on survival, being equal 
in three and better for the high-dose arms in one (51). 
The latter study (51) is a particularly interesting one 
since it compared 40 Gy/10fx (split) to 50 Gy/25fx to 
“wait and see”. The survival in this “wait and see” arm 
was inferior compared to the two actively treated 
arms. While effect on symptoms and palliative effect 
may be similar regardless of dose and fractionation, 
trend of more rapid relief of symptoms in favour of 
hypofractionation is observed with no major difference 
in MST being observed. To investigate the issue whether 
some patients with localised stage III disease may benefit 
from a protracted high-dose RT, a MRC study (51) was 
undertaken which focused only on stage III disease 
with good PS. It compared 17 Gy/2fx (arm 1) with 
39 Gy/13fx (arm 2). The MST increased from 7 to 9 
months in arm 2 (p > .05), with 1- and 2-year survival 
rates of 31 and 9% versus 36 and 12% in arm 1 and 
arm 2, respectively. Another study (44) compared strict 
low-dose to high-dose schedules and found a trend in 
better survival in the high-dose arms. Further analysis 
of the same study (restricted to stage III patients) (53) 
showed three- and five-year survival rates in the three 
arms (17 Gy/2fx, 42 Gy/15fx, 50 Gy/25fx) of 1, 8 and 6%, 
versus 0, 4 and 3%, respectively. Although there was no 
strong evidence that higher dose gives a better outcome 
concerning symptom relief and survival, and that a 
hypofractionated regimen is an option for most patients, 
patients with stage III disease with a reasonable PS and 
less weight loss could be treated with a protracted 
fractionated regimen of 30–45 Gy. General observation 
from all of these studies can be extrapolated to patients 
with stage IV disease which can also safely be treated 
with a hypofractionated schedule. While palliative RT 
aims to treat symptoms from intrathoracic tumours, in 
otherwise symptom-free patients immediate RT may 
have unnecessary side-effects and may not prevent 
development of later symptoms (54, 55). A “wait and 
see” procedure is therefore advocated until the patient 
becomes symptomatic. 
Systemic therapy remains the mainstay of treatment 
of metastatic NSCLC. It is also frequently used in 
poor-risk stage IIIB NSCLC patients presenting with no 
intrathoracic symptoms of the disease. Combination 
CHT with a platinum-based regimen (cisplatin or 
carboplatin) has emerged as standard therapy the 
past few decades (56) and improvements in overall 
survival and quality of life have been demonstrated 
over best supportive care alone (57). Carboplatin-based 
regimens have a favourable tolerability over cisplatin-
based regimens (58, 59). Despite the marginally higher 
response rate with cisplatin-based regimens, carboplatin-
based regimens have found wide applicability in routine 
care. Recent improvements in anti-emetic therapy, 
however, made cisplatin-based regimens more tolerable. 
A number of randomised clinical trials have established 
the superiority of platinum-doublets over single-agent 
therapy (60–62). The “third-generation” cytotoxic agents 
(paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan 
and pemetrexed) have all demonstrated efficacy when 
given in combination with a platinum compound in 
patients with advanced NSCLC (58, 60, 63–66). The 
use of triplets has generally resulted in higher toxicity 
without improved efficacy and has therefore largely been 
abandoned (67). With the currently available platinum-
based two-drug regimens, the MST and one-year survival 
rate are 8–11 months and 30–40% in patients with a 
good PS (68). Choice of systemic therapy based on the 
histological subdivision of NSCLC is a new paradigm. 
It was shown that cisplatin-pemetrexed combination 
was associated with increased efficacy in non-squamous 
NSCLC (69). In patients with adenocarcinoma, the 
median survival with the cisplatin-pemetrexed regimen 
was 12.6 m vs. 10.9 m with cisplatin-gemcitabine (p < 
.05). In addition, this regimen was also associated with 
a favourable tolerability profile. These results led to 
the approval of the cisplatin-pemetrexed regimen for 
patients with only non-squamous NSCLC. Until recently, 
four to six cycles CHT formed the “standard of care” 
for patients with advanced NSCLC (70, 71). Extension 
7of the same treatment failed to demonstrate any 
evidence of benefit. However, success of maintenance 
therapy with pemetrexed or erlotinib administered as 
single agents in stable/responding patients to front-line 
regimen have shifted the treatment paradigm in favour of 
this approach (72, 73). The meta-analysis of maintenance 
therapy studies demonstrates a significant improvement 
in progression-free survival and a modest improvement 
in overall survival (74). Continued controversy among 
lung cancer care providers exists regarding the optimal 
patient type for maintenance therapy and the choice 
of agent (continuation of the same agent vs. switching 
to a new agent). For now “switch maintenance” has 
been established until new data becomes available. 
Patients with poor or declining PS should not be 
offered maintenance therapy (94). EGFR (epidermal 
growth factor receptor) tyrosine kinase inhibitors (TKIs) 
(gefitinib, erlotinib, cetuximab) have all been investigated 
in metastatic NSCLC. While EGFR mutation was shown 
to be the main predictor of outcome with EGFR TKIs 
(76), studies (77–79) excluded a role for combination of 
EGFR TKIs in combination with CHT. Of anti-angiogenic 
agents, bevacizumab was the first targeted agent to 
demonstrate survival advantage in patients with advanced 
stage NSCLC and is now routinely used in the first-
line setting for patients with metastatic non-squamous 
NSCLC. The ECOG 4599 (80) trial tested six cycles 
of carboplatin-paclitaxel with or without bevacizumab 
given as monotherapy for non-progressive patients. The 
overall survival was superior for patients treated with 
bevacizumab (10.3 m. 12.3 m, p = .003). The safety and 
efficacy of bevacizumab has also been documented 
when used in combination with other commonly used 
platinum-based doublets used for the treatment of 
advanced NSCLC (81). Of VEGF (vascular endothelial 
growth factor) receptor inhibitors, when combined with 
CHT, sorafenib (82, 83) and vandetanib (74) were tested 
with modest improvements in outcome, suggesting only 
a possible role of various VEGF receptor inhibitors with 
more clinical trial testing.
In the SCLC domain, in limited disease (LD), two meta-
analyses that appeared more than two decades ago (85, 
86) showed small but significant improvement in two-
year and three-year survival rates, averaging 5–7% with 
combined RT-CHT. Importantly, the widespread use of 
cisplatin/etoposide, and its low toxicity when combined 
with RT, made more effective use of concurrent RT and 
platinum-based CHT, which is nowadays considered 
as the standard treatment in LD SCLC. In addition, 
almost 15 years ago meta-analysis (87) established the 
necessity to incorporate prophylactic cranial irradiation 
(PCI) as a mandatory part of the combined treatment. 
Due to its pronounced chemosensitivity, there are many 
CHT agents which achieve response rates of > 30% 
in SCLC. They include cisplatin, carboplatin, etoposide, 
cyclophosphamide, doxorubicin, methotrexate and 
vincristine (88). In a phase III study, cisplatin/etoposide 
appeared superior to cyclophosphamide, epirubicin 
and vincristine in a randomised study. The five-year 
survival rates were 5% and 2% in the two treatment 
arms, respectively (p = .0004) (89). The use of cisplatin/
etoposide in this disease has been additionally supported 
by a systematic review using 36 randomised trials which 
have tested single-agent cisplatin or etoposide or both 
(doublet) against regimens not containing these agents. 
The significant improvement with use of these drugs in 
comparison with CHT with neither was demonstrated 
(90). Approaches to intensify the dose of CHT by giving 
higher doses (91), occasionally including granulocyte 
colony-stimulating factor support (92) or by decreasing 
the interval between the cycles of CHT (93) or even 
using bone marrow support (94), all showed promising 
results. However, they were always and unequivocally 
accompanied with high toxicity, which prevented it 
becoming standard treatment approach. Investigation 
of the place and role of third-generation drugs (e.g. 
topotecan, paclitaxel) showed they had no impact on 
survival (95, 96). When timing of combined RT and 
CHT is considered, some studies (97, 98) suggested that 
RT delayed until the fourth cycle of CHT (97) or later 
may be superior to initial RT or suggested no difference 
when compared to early RT and CHT (98). More recent 
studies using cisplatin/etoposide (99–101) showed clear 
superiority for early administration of RT (concurrently 
given during the first or second cycle of CHT) since it 
was capable of achieving five-year survival rates of > 
20%, whilst late RT usually obtained only about 10%. 
Recently, several meta-analyses and systematic reviews 
(102–104) brought somewhat conflicting results which 
were largely resolved by Jeremic (105) who performed 
“meta-analysis of the meta-analyses”, who showed that 
early hyperfractionated RT and four courses of CHT 
based on cisplatin-etoposide should be practiced as 
standard approach. Regarding RT dose and fractionation, 
total doses were usually about 50 Gy, given daily, but 
ranged from as low as 30 Gy to as high as 70 Gy. In 
addition, many recent studies have used some form of 
hyperfractionation (b.i.d.). In the Intergroup study (106), 
45 Gy given in 30 fractions in three weeks (1.5 Gy b.i.d. 
fractionation) was compared with the same dose given 
once daily, both with concurrent cisplatin-etoposide CHT. 
The survival was significantly better in the b.i.d. arm (five-
year survival rate, 26% versus 19%). Hypofractionated 
RT regimens were also used, thought to cause more 
damage to SCLC cells (101). Currently, two major 
clinical trials investigating this issue are recruiting patients 
8(CONVERT of the EORTC in Europe and CALGB 
30610/RTOG 0538 in the USA) by directly comparing 
the same hyperfractionated regimen with either the 
conventional or concomitant boost regimen. 
For decades, clinicians and investigators considered 
platinum-etoposide CHT the standard treatment option 
for patients with ED SCLC. As an exclusive treatment, 
it can offer the median survival time of 9–12 months 
and five-year survival rates of 1–3% (107, 108). While 
up to 90% of patients eventually respond following initial 
courses of CHT, most of patients unfortunately relapse. 
Therefore, various approaches aiming intensification 
of the treatment were attempted. Unfortunately, 
maintenance CHT after four to six initial cycles with or 
without adding the third-generation drug (95, 109, 110) 
and higher doses of CHT (94, 111) did not prove to be 
beneficial in this setting. Adding a third CHT agent or using 
targeted agents also did not result in any improvement. 
Recent findings of Slotman et al. (112), however, changed 
the practice in ED SCLC by showing that PCI offer 
significant brain-metastasis-free survival, relapse-free 
survival and overall survival in patients after achieving 
any response after induction CHT. It is now accepted 
worldwide as standard treatment option in responding 
patients with ED SCLC. The case for curative RT in 
ED SCLC is still an unsolved issue and is under active 
investigation. Although patients treated with CHT alone 
in ED SCLC frequently experience chest relapses, even 
in case of previous complete response, RT had not been 
systematically investigated in this setting. The systemic 
character of ED SCLC may also obscure possible effects 
of RT on survival (if previously established on a local 
level). The role of RT was evaluated in a prospective 
randomised trial by Jeremic et al. (108). After three cycles 
of CHT, complete patient re-evaluation and restaging 
was performed and patients were then randomised 
to receive either RT and concurrent CHT, followed by 
PCI (group I) or continue with four additional cycles of 
cisplatin-etoposide and PCI (group II). The MST was 17 
vs. 11 months (p = .041), and five-year survival rates 
were 9.1 and 3.7% for groups I and II, respectively. This 
study (108) was the very first to show that RT may play a 
substantial role in the treatment of ED SCLC. Emerging 
reports worldwide confirm this observation. Both Yee et 
al. (113) and Zhu et al. (114) provided confirmatory data 
of the study of Jeremic et al. (108). Recently, Ou et al. 
(115) retrospectively analysed the data from Southern 
California to document the use of RT in ED SCLC in 
35.1% patients. The two-year survival rate and MST were 
9.3% and 8 months, respectively; significantly better than 
corresponding figures in patients who did not receive 
RT (3.8% and 4 months, respectively; p < .0001). Two 
large on-going studies (RTOG in the USA and CREST in 
Holland) will provide further insight into this issue.
 REALITIES vs. OPPORTUNITIES
Technological and biological advances in the field 
of non-surgical treatment of lung cancer and current 
standards of care in this disease must, however, be 
placed into the context of both existing realities and 
opportunities of the Division of Radiation Oncology 
of Stellenbosch University and its affiliated Tygerberg 
Hospital. Realities include the following:
1.    Limited resource setting of a developing country:
 a. Only three linear accelerators (LINACs) 
exist to treat more than 2000 new cancer 
patients annually, the oldest LINAC being more 
than 25 years old; hence, both limited access 
to RT (with resulting long waiting lists) and lack 
of modern RT techniques available on modern 
LINACs 
 b. Limited access to modern drugs, which are 
deemed “too expensive” (not cost-effective), 
although majority of them (e.g. paclitaxel) are 
not so, since they already exist in generic forms
 c. Limited available space in the Division 
(Building X) for active or supportive treatment 
of lung cancer patients
2. Poor awareness of lung cancer and poor 
healthcare infrastructure:
 a. Frequent delay in both diagnosis and referral 
 b. Usual advanced disease at presentation 
(advanced NSCLC or ED SCLC); hence, a 
substantial number of patients are treated 
palliatively
 c. Strong dependence on transport aspects 
of cancer patients, resulting in “missing” 
appointments and missing treatment days (of 
RT and/or CHT), including frequent observation 
of “patient lost to follow-up”
d. Lack of appropriate communication with 
peripheral oncologists and non-oncologists 
in the process of follow-up and, if necessary, 
treatment of cancer- unrelated diseases and 
conditions
9Opportunities include the following:
1.   Improvement in existing logistics and infrastructure 
at SU/TBH:
 a. Weekly Multidisciplinary (Lung) Disease 
Team (MDT) meetings with presentation of 
new cases in front of a panel of various lung 
cancer specialists
 b. Updated (as of February 2013) lung 
cancer diagnostic and therapeutic protocols (in 
collaboration with other SU/TBH services)
 c. Newly formed Lung Cancer Group with 
various specialists working professionally and 
scientifically on the lung cancer problem
 d. A list of professional and scientific meetings 
proposed to be organised on national and 
international level (starting in October 2013)
 e. Initial efforts aiming to address the need for 
a lung cancer database
 f. Improved collaboration with existing non-
clinical services of SU/TBH (e.g. radiobiology, 
pharmacology)
2. Partially available new and modern technology:
 a Introduction of a Big Bore CT scanner 
exclusively dedicated to treatment planning 
purposes with available “gating” component, 
helping better delineation of the tumour 
volumes during breathing cycles; however, 
“gating” is available only for tumour delineation 
(planning) process and not for treatment
 b. Introduction of PET-CT in treatment 
planning of lung cancer patients, with or without 
“gating”
 c. Introduction of IMRT in selected cases, with 
or without “gating”
3. Identification of priority areas in the research of 
lung cancer:
 a Existing equipment would pinpoint to the 
4D in planning of RT of lung cancer as well as 
using PET-CT in 3D and 4D treatment planning 
of lung cancer and eventually to IMRT
 b. Existing type of patients would pinpoint 
research focusing upon:
 i. Patients with atelectasis
 ii. Patients with HIV and/or TB
 iii. Patients with poor performance status (e.g. 
PS3)
 iv Short fractionation RT regimen and short 
(low-toxic) CHT
 v. Recurrent cancers treated with either 
protons and/or novel drugs
4. Publication of papers in national and international 
journals
CONCLUSIONS
Lung cancer is one of the major cancer types seen 
at SU/TBH and definitely the deadliest one. In spite 
of serious limitations, opportunities clearly exist for 
a systematic and orchestrated approach in clinic, 
education and research in this field. Working on this 
problem on interdisciplinary and interprofessional 
level remains the main objective for oncology at SU/
TBH, with expertise and dedication as necessary 
ingredients for overall success.
10
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